Order results by:
| Issue | Title | |
| Vol 14, No 3 (2021) | COVID-19 pandemic prediction model based on machine learning in selected regions of the Russian Federation | Abstract similar documents |
| D. V. Gavrilov, R. V. Abramov, А. V. Kirilkina, А. А. Ivshin, R. E. Novitskiy | ||
| "... of COVID-19 cases and deaths in the Russian Federation. Material and methods. The data for the model ..." | ||
| Vol 14, No 2 (2021) | Impact of disease information (Ebola and COVID-19) on the pharmaceutical sector in Russia and USA | Abstract similar documents |
| E. A. Fedorova, D. O. Afanasyev, A. V. Sokolov, M. P. Lazarev | ||
| "... and methods. The empirical base of the study includes more than 700 thousand tweets on Ebola and COVID-19 ..." | ||
| Vol 9, No 1 (2016) | MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016 | Abstract similar documents |
| A. S. Kolbin, A. V. Prasolov, E. A. Maksimkina, Yu. E. Balykina, Z. M. Golant, Yu. S. Polushin, A. A. Kurylev, I. A. Vilyum | ||
| "... included into the reimbursement lists acting from 2016. The model of expert body decision had an error 7 ..." | ||
| Vol 6, No 2 (2013) | HTA CORE MODEL | Abstract similar documents |
| R. I. Yagudina, T. Yu. Nor, A. D. Sevostyanov | ||
| "... The EUnetHTA Core Model is an electronic system of standardized health technology assessment ..." | ||
| Vol 13, No 4 (2020) | Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm | Abstract similar documents |
| M. Yu. Frolov, A. S. Salasyuk, V. A. Rogov | ||
| "... )-6 drugs: tocilizumab, olokizumab, and levilimab in patients with severe COVID-19 and cytokine storm ..." | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy | Abstract similar documents |
| M. V. Zhuravleva, V. P. Chulanov, Yu. V. Gagarina, E. A. Shabalina | ||
| "... or their combinations vs standard therapy in patients with mild and moderate-severe COVID-19 in order to prevent ..." | ||
| Vol 17, No 2 (2024) | Mathematical modeling and analysis of export trends for certain pharmaceutical groups | Abstract similar documents |
| А. R. Shaikhislamova, N. А. Gasratova | ||
| "... , and measures of protectionism. The relative error of Model I does not exceed 10%, which makes it suitable ..." | ||
| Vol 7, No 2 (2014) | PARAMETERS OF HEALTH CARE SYSTEMS | Abstract similar documents |
| V. V. Omelyanovskiy, I. V. Maksimova, A. P. Tatarinov | ||
| "... selection of the best model of health care to ensure more efficient use of resources to improve ..." | ||
| Vol 14, No 1 (2021) | Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19 | Abstract similar documents |
| O. V. Zhukova, A. L. Khokhlov | ||
| "... Background. Severe forms of COVID-19 are associated with the development of a cytokine storm ..." | ||
| Vol 15, No 3 (2022) | Economic burden of the novel coronavirus infection: a systematic review | Abstract similar documents |
| V. M. Timiryanova, I. A. Lakman, N. Sh. Zagidullin, D. F. Gareeva | ||
| "... Background. The sudden emergence and rapid spread of the novel coronavirus infection (COVID-19 ..." | ||
| Vol 7, No 4 (2014) | MODELING IN CLINICO-ECONOMIC ANALYSIS OF MEDICAL ORGANIZATIONAL TECHNOLOGIES | Abstract similar documents |
| M. A. Shapovalova, A. R. Umerova, V. A. Bondarev, L. R. Koretskaya | ||
| "... decision tree and Markov model we used for calculating the anticipated costs when comparing two ..." | ||
| Vol 12, No 3 (2019) | Diagnosis-related groups and payments for the treatment of malignant neoplasms in the model of 2019 | Abstract similar documents |
| D. V. Fedyaev , V. V. Omelyanovskiy , M. L. Lazareva , Yu. V. Seryapina, Yu. A. Ledovskikh | ||
| "... The article addresses the model of diagnosis-related groups (DRG) updated according to the new ..." | ||
| Vol 16, No 2 (2023) | Development of methodological approaches to the formation of a risk-based model to minimize the prevalence of adverse reactions in drug application in medical organizations of Moscow | Abstract similar documents |
| E. V. Kuznetsova, M. V. Zhuravleva, I. A. Mikhailov, T. I. Kurnosova | ||
| "... . Results. The results were visualized in the form of a two-level risk-based model matrix, with a “heat map ..." | ||
| Vol 13, No 4 (2020) | Development of a method for calculation of demand for medical personnel in the healthcare of the Russian Federation, using a mathematical model | Abstract similar documents |
| V. V. Omelyanovsky, T. V. Semenova, D. V. Lukyantseva, D. V. Fedyaev, E. A. Shalaeva | ||
| "... a mathematical model of human resource for healthcare HRH balancing. Materials and methods. As part of the study ..." | ||
| Vol 17, No 2 (2024) | Study of lithium carbonate and ascorbate proliferative properties on transplantable Lewis lung carcinoma metastasis model | Abstract similar documents |
| D. E. Frolova, I. Yu. Torshin, V. V. Rastashansky, M. V. Filimonova, O. A. Gromova | ||
| Vol 17, No 4 (2024) | Study of the effect of human placenta hydrolysate in a new model of metabolic-associated fatty liver disease with iron overload | Abstract similar documents |
| T. E. Bogacheva, O. A. Gromova, I. Yu. Torshin, V. I. Demidov, A. G. Kalacheva, A. A. Garanin, I. V. Gogoleva, L. E. Fedotova, O. A. Limanova, А. N. Mnatsakanyan, N. Yu. Zhidomorov, T. R. Grishina | ||
| "... that no specific treatments have been developed for this МAFLD form, there are also few experimental models ..." | ||
| Vol 6, No 2 (2013) | FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS | Abstract similar documents |
| A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure | ||
| "... Goal: to develop the model of of type 2 diabetes mellitus outcomes validated in Russian clinical ..." | ||
| Vol 17, No 2 (2024) | Methodology of forming a model of diagnosis-related groups for cases of medical care using surgery performed by laparoscopic access | Abstract similar documents |
| I. A. Zheleznyakova, O. A. Volkova, E. I. Rumiantseva, I. A. Mikhailov, D. V. Fedyaev, A. V. Zuev, O. S. Plakhotnik, G. V. Trifonova, T. S. Vakhrusheva, E. S. Samsonova, V. V. Omelyanovskiy | ||
| "... . Objective: to develop a methodology for the formation of a DRG model for cases of medical care using surgery ..." | ||
| Vol 5, No 2 (2012) | COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS | Abstract similar documents |
| A. V. Rudakova | ||
| Vol 15, No 2 (2022) | Experience of implementing a value-based approach in oncodermatology | Abstract similar documents |
| Yu. A. Zuenkova, D. I. Kicha, L. N. Izyurov | ||
| "... (Rasch psychometric model). Younger patients (r=–0.398, p=0.009) and female patients (r=–0.475, p=0 ..." | ||
| Online First | Antitumor effects of vitamin B12 in vitro, in vivo, in silico | Abstract similar documents |
| O. A. Gromova, D. E. Frolova, I. Yu. Torshin, M. V. Filimonova, M. A. Sorokina, I. A. Reyer, O. A. Limanova, L. E. Fedotova, L. A. Maiorova | ||
| "... model, and transplantable epidermoid Lewis lung carcinoma (LLC) was used as an in vivo animal tumor ..." | ||
| Vol 13, No 3 (2020) | The use of various genetically engineered biological drugs and selective immunosuppressants within the current provider-payment model of russian diagnosis-related groups | Abstract similar documents |
| E. V. Derkach, E. A. Pyadushkina, M. V. Avxentyeva, T. V. Boyarskaya, E. E. Yagnenkova, A. S. Mokrova, M. M. Maryanyan | ||
| "... possible applications of different GEBD and SI within the current provider-payment model of the Russian ..." | ||
| Vol 11, No 2 (2018) | Regional adaptation of the federal model of reimbursement for medical assistance based on clinical statistical groups: hospitalization of patients in need of genetically enginered biological preparations | Abstract similar documents |
| M. V. Sura, T. N. Ignatova, N. S. Rudneva, Yu. N. Sukhanova, N. G. Ulyanova, A. S. Khudyaev, V. A. Shelyakin, D. V. Scherbakov | ||
| "... The existing model of financial support of medical assistance for clinical-statistical groups (CSGs ..." | ||
| Vol 9, No 1 (2016) | PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX-GASTAUT SYNDROME TREATMENT | Abstract similar documents |
| N. K. Mazina, P. V. Mazin, Yu. V. Kislitsin, E. M. Markova | ||
| Vol 10, No 3 (2017) | The strategies of drug supply for patients with chronic hepatitis C | Abstract similar documents |
| E. V. Kornilova, A. D. Ermolaeva, M. G. Rusanova, D. A. Andreev, M. V. Davydovskaya, T. N. Ermolaeva, A. g Pokatilo, K. I. Polyakova, V. A. Dubovtseva, K. А. Kokushkin, A. V. Devyatkin | ||
| Vol 11, No 4 (2018) | Clinical and economic studies on pharmacotherapy of malignant neoplasms: the modeling approach | Abstract similar documents |
| A. G. Tolkushin, S. K. Zyryanov, N. L. Pogudina, M. V. Davydovskaya | ||
| "... special attention to the model type, the modeling methodology, information on the effectiveness and cost ..." | ||
| Vol 16, No 2 (2023) | Сlinical and economic evaluation of various etiotropic chemotherapy regimens in patients with respiratory tuberculosis with multidrug and extensively drug resistance | Abstract similar documents |
| N. Yu. Nikolenko, D. A. Kudlay, S. E. Borisov, T. E. Sannikova, N. P. Doktorova | ||
| "... ) pathogen using the pharmacoeconomic modeling method (Markov model). Material and methods. A single-centre ..." | ||
| Vol 14, No 2 (2021) | Chemoreactome screening of pharmaceutical effects on SARS-CoV-2 and human virome to help decide on drug-based COVID-19 therapy | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova, A. G. Chuchalin, Yu. I. Zhuravlev | ||
| "... and safe drug-based treatment for COVID-19. Another approach seems promising: to reprofile ..." | ||
| Vol 16, No 2 (2023) | Improving the model of payment for medical care for chronic viral hepatitis C in the framework of the implementation of the Program of State Guarantees of Free Provision of Medical Care to Citizens for 2023 and for the planned period of 2024–2025 | Abstract similar documents |
| V. V. Omelyanovskiy, I. A. Zheleznyakova, A. V. Zuev, O. S. Plakhotnik, O. A. Volkova, L. M. Davydova, G. V. Trifonova, E. V. Semakova, E. A. Prokhorovich, A. S. Volkova | ||
| "... HCV is based on modern drugs of direct-acting antivirals (DAA). In this regard, the model of diagnosis ..." | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic aspects of COVID-19 treatment | Abstract similar documents |
| I. V. Rogova, E. A. Zhidkova, I. A. Popova, A. V. Zaborovskiy, K. G. Gurevich | ||
| "... The article provides an overview of global trends in various treatment approaches for COVID-19 ..." | ||
| Vol 9, No 3 (2016) | COPAYMENTS OF THE CITIZENS IN HEALTHCARE SYSTEM: INTERNATIONAL PRACTICE | Abstract similar documents |
| A. P. Tatarinov, D. V. Lukyantseva, L. S. Melnikova, V. V. Omelyanovskii | ||
| Vol 13, No 2 (2020) | COVID-19 pandemic: protective role of vitamin D | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, G. Kh. Gabdulina | ||
| "... Introduction. The COVID-19 pandemic revealed the vulnerability of the general population ..." | ||
| Vol 16, No 1 (2023) | Efficiency of Levilimab in patients with moderate and severe COVID-19 | Abstract similar documents |
| Yu. M. Gomon, V. V. Strizheletsky, I. G. Ivanov, Yu. E. Balykina, M. V. Ermolyev, A. S. Kolbin, M. V. Livshits, T. A. Usmanova, A. M. Fakhrutdinova, Yu. S. Konstantinova, A. P. Gubanov | ||
| "... of moderate and severe COVID-19 based on real world data (RWD). Material and methods. A single-center ..." | ||
| Vol 15, No 4 (2022) | Dietary factors influencing the COVID-19 epidemic process | Abstract PDF (Eng) similar documents |
| S. V. Ponomarenko | ||
| "... Coronavirus and identify factors that correlate withthe reduction in the severity of the consequences of COVID ..." | ||
| Vol 15, No 1 (2022) | A systematic review of real-world clinical practice data in COVID-19: non-interventional studies | Abstract similar documents |
| S. A. Mishinova, Yu. M. Gomon, A. S. Kolbin, V. V. Strizheletsky, I. G. Ivanov | ||
| "... . A search strategy for the terms “COVID-19 AND real-life”, “COVID-19 AND real-data”, “COVID-19 AND real ..." | ||
| Vol 15, No 2 (2022) | Clinical study of real-time polymerase chain reaction test kit for SARS-CoV-2 ribonucleic acids detection | Abstract similar documents |
| M. Yu. Dmitryukova, A. A. Golod, M. E. Senina, A. E. Gushchin | ||
| Vol 16, No 1 (2023) | Non-invasive respiratory support in patients with severe community-acquired pneumonia | Abstract similar documents |
| S. V. Korotchenko, D. I. Korabelnikov | ||
| "... forms of COVID-19. At the beginning of COVID-19 pandemic the starting respiratory protocol suggested ..." | ||
| Vol 13, No 4 (2020) | Peptides contained in the composition of Laennec that contribute to the treatment of hyperferritinemia and iron overload disorders | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, V. A. Maksimov, A. G. Chuchalin, V. G. Zgoda, А. N. Gromov, O. V. Tikhonova | ||
| Vol 14, No 4 (2021) | Development of the system of state financing of Compulsory Health Insurance | Abstract similar documents |
| А. V. Larionov, S. V. Russkikh, S. V. Maslennikov | ||
| Vol 17, No 4 (2024) | Scenario modeling of the drug prescription process for children: application of machine learning methods | Abstract similar documents |
| А. А. Kondrashov, М. М. Kurashov, Е. Е. Loskutova | ||
| "... and define the process as a multi-label classification task. The following model architectures were developed ..." | ||
| Vol 8, No 2 (2015) | REVIEW OF THE INTERNATIONAL PRACTICE OF COST-SHARING MECHANISM IN NATIONAL HEALTH CARE SYSTEMS | Abstract similar documents |
| Natalia Nikolayevna Sisigina, Vitalii Vladimirovich Omel'yanovskii, Nikolay Alexandrovich Avxentyev | ||
| "... mechanisms for vulnerable social groups, national cost-sharing models are considered. ..." | ||
| Vol 15, No 3 (2022) | Funding for coronavirus health worker payments | Abstract similar documents |
| I. Yu. Bocharova, A. Yu. Rymanov | ||
| "... Objective: to conduct an analysis of the channels, the volume of COVID payments to medical workers ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomical analysis of use of the low-molecular weight heparins for prevention of the venous tromboembolism in the conditions of multidisciplinary hospital | Abstract similar documents |
| A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina | ||
| "... , two pharmacoeconomic models were constructed. The main model evaluated efficacy of thromboprophylactic ..." | ||
| Vol 10, No 3 (2017) | Decision modelling for the evaluation of diabetes outcomes | Abstract similar documents |
| A. A. Mosikian, W. Zhao, T. L. Galankin, A. S. Kolbin | ||
| "... DM decision models and on the validity of extrapolating the type 2 DM models to patients with type 1 ..." | ||
| Vol 6, No 2 (2013) | PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION | Abstract similar documents |
| V. A. Chibilyaev, A. Yu. Kulikov, R. I. Yagudina | ||
| "... B), which differ with the expansion of access to ART was conducted using deterministic model ..." | ||
| Vol 8, No 4 (2015) | CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS | Abstract similar documents |
| E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva | ||
| "... (ITP) at the background failure of previous treatment options. Materials and methods. Two models ..." | ||
| Vol 17, No 3 (2024) | Review of open libraries for pharmacoeconomic analysis in R environment | Abstract similar documents |
| I. A. Lackman, R. I. Sladkov, V. M. Timiryanova | ||
| "... interventions based on decision tree algorithms and Markov models. The libraries “heemod”, “hesim”, “rdesign ..." | ||
| Vol 8, No 1 (2015) | PAYMENT OF NEW EXPENSIVE TECHNOLOGIES IN HEALTH CARE ON THE BASIS OF RISKS -SHARING AGREEMENTS: POSSIBILITIES OF APPLICATION IN THE RUSSIAN FEDERATION | Abstract similar documents |
| L. S. Melnikova | ||
| "... The article sets out the results of analysis of existing models of risk sharing agreements, which ..." | ||
| Vol 9, No 1 (2016) | PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... Excel model. CER compared lenvatinib 24 mg/daily, sorafenib 800 mg/daily and Other chemotherapies mix ..." | ||
| 1 - 50 of 137 Items | 1 2 3 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
